BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

 BMS Presents Results of Mavacamten in P-III Study for Obstructive Hypertrophic Cardiomyopathy at ACC 2021

BMS Presents Results of Opdivo (nivolumab) + CT or Yervoy (ipilimumab) in P-III CheckMate -648 Trial for Unresectable Advanced or Metastatic ESCC at ASCO 2021

Shots:

  • The P-III EXPLORER-HCM study involves assessing Mavacamten vs PBO in 251 patients in a ratio (1:1) with symptomatic oHCM (LVOT gradient ≥50 mmHg and NYHA Class II-III) for 30wks, followed by an 8-week washout
  • Results: @30wks. change in KCCQ OSS in greater than PBO arm; KCCQ OSS ≥20 points (36% vs 15%); a greater proportion of patients in the placebo arm had no change or deterioration in their health status
  • Mavacamten is an investigational, first-in-class cardiac myosin inhibitor, in patients with oHCM. The findings of the new analysis are published in the Lancet

Click here to­ read full press release/ article | Ref: Businesswire | Image: Fierce Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post